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SCID model, comparing transplantation of 1  106 CD34 cells,
cotransplantation of 5  105 untransduced mesenchymal cells and
1  106 CD34 cells and cotransplantation of 5  105 IL-7
engineered stromal cells with 1  106 CD34 cells, the last
improved engraftment in terms of CD45 cells and signiﬁcantly
increased the CD3 cell count in peripheral blood (1.4 	 1.6 vs
7.4 	 3; P  .05), bone marrow (0.8 	 1 vs 5.5 	 2; P  .05) and
spleen (0.08 	 0.1 vs 6.2 	 2; P  .05). No signiﬁcant differences
emerged in CD19 cell recovery. IL-7 serum concentrations did
not vary at any time point posttransplantation. These data dem-
onstrate that IL-7-transduced stromal cells maintain the naive
T-cell phenotype (CD45RA/CD45RO) in vitro and serve to
improve immunologic reconstitution after HSCT in NOD/SCID
mice, thus emerging as an ideal scaffold for hastening immunolog-
ical recovery in T-cell-deﬁcient hosts.
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LIMITING ALLOGENEIC BONE MARROW TRANSPLANTATION BASED
ON PSYCHOSOCIAL CRITERIA: A COMPARISON OF PROFESSIONAL AT-
TITUDES
McLellan, L.1; Foster, L.2; Kuczkowski, E.1; Dabney, J.1; Welsh, E.1;
Bell, K.1; Rini, B.1; Bates, J.1; Curtis, J.1; Bolwell, B.J.1 1. The
Cleveland Clinic Foundation, Cleveland, OH; 2. Cleveland State Uni-
versity, Cleveland, OH.
Oncologists specializing in bone marrow transplantation (BMT)
make decisions about who is an appropriate medical candidate for
an allogeneic BMT based on clinical criteria. It is not clear how
and if decisions are made as to whether a patient is an appropriate
candidate based on psychosocial criteria. Although setting limits
based on such criteria has been researched in solid organ trans-
plantation, this is not the case in BMT. Presented will be results
from survey research comparing responses of BMT physicians,
social workers, and nurses regarding acceptability of select psycho-
social screening criteria in allogeneic BMT. An IRB-approved
survey was mailed to members of ASBMT (North America),
AOSW, BMT Special Interest Group, and ONS BMT Special
Interest Group. Respondents were asked whether they would rec-
ommend proceeding or not proceeding with allogeneic BMT in 17
case vignettes, all of in which the patient has leukemia and had a
matched donor. Based on 262 physician surveys returned (40%
response rate), the following are 7 case vignettes in which the
majority stated that they would recommend not proceeding: active
suicidal ideation (84%), current use of addictive illicit drugs (76%),
noncompliance (76%), no caregiver available posttransplantation
(69%), active alcoholism (61%), early onset of Alzheimer’s disease
(55%), and no means to pay for BMT (51%). In 10 of 17 case
vignettes, most physician respondents would recommend proceed-
ing: history of prior suicide attempts but not currently suicidal
(86%), mild mental retardation (84%), major depression (84%),
controlled schizophrenia (82%), daily marijuana use (82%), history
of a violent felony crime (81%), borderline personality disorder
(79%), tobacco smoking (79%), morbid obesity (71%), and care-
giver with mental health problem (65%). These initial ﬁndings
infer that whether or not physicians decide to proceed with allo-
geneic BMT may be contingent on the currency and acuity of
psychosocial risk factors predictive of impaired patient ability for
informed, competent decision-making. Responses of physicians,
nurses, and social workers are compared and implications for
clinical practice in BMT discussed.
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HSCT FAMILY CAREGIVER QUALITY OF LIFE INFLUENCED BY HIGH
CAREGIVING STRAIN AND LOW PREDICTABILITY OF CAREGIVING
Eldredge, D.H.1, Nail, L.M.1, Grant, M.2, Maziarz, R.T.1 1. Oregon
Health Science University, Portland, OR; 2. City of Hope Comprehensive
Cancer Center, Duarte, CA.
Background/Purpose: Family caregivers (FCGs) provide much
of the outpatient care for allogeneic HSCT recipients during the
ﬁrst year after transplantation. Despite the importance of family
caregiving, there is little information about the types of care ac-
tivities required during this period and the effect of caregiving role
strain (CRS) on FCGs’ quality of life (QOL). The purpose of this
study is to describe relationships among preparedness for caregiv-
ing, predictability of caregiving, recipient function and CRS on
FCG QOL. Methods: FCGs (N  56) were recruited from 2
academic medical centers on the West Coast and completed a
single questionnaire between 3 and 15 months (mean, 7.7 months)
after family members’ allogeneic HSCT. Descriptive statistics,
correlation, and simultaneous regression techniques were used in
this cross-sectional study. Results: Three types of caregiving were
inductively derived from 100 activities: (1) performing usual care
(eg, supervising scheduled medications, keeping house clean), (2)
providing emotional support (eg, talking with HSCT recipients
when sad, discussing how people respond to recipients’ illness), and
(3) making care-based decisions (eg, giving prn medications, no-
ticing subtle changes). Providing emotional support was the most
difﬁcult type of caregiving activity (mean, 1.81; range, 0  not
done, 1  easy, to 5  very hard). FCGs had little difﬁculty
performing usual care (mean, 0.90) and making care-based deci-
sions (mean, 1.28). FCGs felt moderately well prepared for care-
giving (mean, 2.9; range, 1–4). Together, preparedness, recipient
function, predictability, and the 3 types of caregiving accounted for
37% of the variance in FCG QOL (F6,48 7.3; P  .001). FCG
QOL was uniquely predicted by predictability of caregiving (t48 
2.5; P  .02) and strain from providing emotional support (t48 
1.9; P .05). Conclusions:During the ﬁrst year after allogeneic
HSCT, FCGs need ongoing assistance providing emotional sup-
port to HSCT recipients and recognizing predictability of recipi-
ents’ caregiving needs.
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EARLY ALLOGENEIC STEM CELL TRANSPLANTATION FOR YOUNG
ADULTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE
REMISSION: AN INTENT-TO-TREAT ANALYSIS OF THE LONG-TERM
EXPERIENCE OF THE BGMT GROUP
Jourdan, E.1; Boiron, J.M.2; Dastugue, N.3; Vey, N.4; Marit, G.2;
Rigal Huguet, F.3; Molina, L.5; Fegueux, N.6; Pigneux, A.2; Recher,
C.3; Rossi, J.F.6; Attal, M.3; Sotto, J.J.5; Maraninchi, D.4; Reiffers, J.2;
Bardou, V.J.4; Blaise, D.4 1. Centre Hospitalier de Caremeau, Nimes,
France; 2. Groupe Hospitlier du Haut Leveque, Bordeaux, France; 3.
Hopital Purpan, Toulouse, France; 4. Institut Paoli-Calmettes, Mar-
seille, France; 5. Hopital Michalon, Grenoble, France; 6. Hopital Lap-
eyronie, Montpellier, France.
We evaluated the outcome of early allo-SCT through 4 succes-
sive protocols over 17 years by an intent-to-treat analysis based on
donor availability in patients younger than 45 years with CR1
AML. Of the 472 patients achieving CR, 182 had an HLA-iden-
tical sibling identiﬁed, and allo-SCT was carried out in 171 (94%)
after Cy-TBI. Of the 290 patients without donor, 88% were
intended (and 63% received) to receive autologous auto-SCT.
With a median follow-up of 114 months, the 10-year probabilities
of relapse, nonrelapse death, overall survival (OS), and leukemia-
free survival (LFS) were 27% versus 55% (P  .001), 24% versus
6% (P  .001), 51% versus 43% (P  .11), and 48% versus 40%
(P  .03), respectively, for alloSCT and non-alloSCT treatment.
Cox analysis identiﬁed initial WBC, FAB subtypes, cytogenetic
risk group, and number of induction courses to achieve CR as
signiﬁcant prognostic predictors. We calculated the statistical risk
of each combination of these 4 factors for patients not having a
suitable donor and identiﬁed 3 groups of patients with different
outcome (poor, intermediate, and standard risk group). This anal-
ysis allowed us to reclassify 21% of the patients as compared with
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the standard cytogenetics classiﬁcation (unfavorable, intermediate,
favorable). We then compared each of this subgroup with the
corresponding population of patients presenting the same risk
factors but owning a HLA identical sibling. In the standard risk
group (n  66), no-donor patients presented a favorable 10-year
survival (74%) compared with patients with a donor (51%) (P 
not signiﬁcant), and allo-SCT should not be recommended. In the
poor risk group (n  131), patients without a donor presented a
poor outcome (10-year OS  17%), which was not better if a
donor existed (28%) (P  .29); in these patients with a poor
outcome whatever the treatment, investigational studies should be
recommended. In the intermediate risk group (n  275), allo-SCT
offered a better outcome; the 10-year probabilities of relapse,
nonrelapse death, OS, and LFS (no donor vs donor) were 47%
versus 18% (P  .0001), 7% versus 17% (P  .02), 47% versus
63% (P  .02), and 45% versus 64% (P  .001), and the 10-year
OS was 56% versus 41% (P  .01). Allo-SCT represent a real
chance of long-term outcome and might beneﬁt from recent ad-
vances. We conclude that long-term outcome might be achieved in
some subgroups of patients and that the indication for allo-ASCT
could be assessed trough a simple classiﬁcation based on common
parameters.
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TOTAL BODY IRRADIATION (TBI) AND G-CSF-COMBINED HIGH-DOSE
CYTARABINE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOGE-
NOUS LEUKEMIA (AML) AND ADVANCED MYELODYSPLASTIC SYN-
DROME (MDS)
Mori, T.; Yokoyama, A.; Aisa, Y.; Yamane, A.; Yamazaki, R.; Naka-
zato, T.; Ikeda, Y.; Okamoto, S. Division of Hematology, Keio University
School of Medicine, Tokyo, Japan.
The most common reason for failure in later-stage patients after
allogeneic hematopoietic stem cell transplantation (allo-HSCT)
for AML and advanced MDS is leukemic relapse, demonstrating
the inability of preparative regimen to completely eradicate leuke-
mic cells. We report the outcome of allo-HSCT for myeloid
malignancies using myeloablative preparative regimen including
TBI and high-dose cytarabine. In addition, granulocyte colony-
stimulating factor (G-CSF) was simultaneously administered with
cytarabine to increase the susceptibility of leukemic cells to cytar-
abine. Patients and Methods: Patients with myeloid malignan-
cies, including AML, AML evolving from MDS, and advanced
MDS (RAEB, RAEB-t, CMML) were eligible. For conditioning,
patients received TBI (12 Gy) followed by intravenous high-dose
cytarabine (3g/m2 every 12 hours for 4 consecutive days). Recom-
binant G-CSF (lenograstim; 5 g/kg/day) was administered intra-
venously by continuous infusion for 4 days, starting 12 hours
before the ﬁrst dose of Ara-C and continued until the last dose of
Ara-C. For the prophylaxis of acute graft-versus-host disease, cy-
closporine A or tacrolimus with or without short-term methotrex-
ate was given. Results: Seventy-nine patients were evaluable, with
a median age of 39 years (range, 15–58 years). Their diagnoses
were AML in 57, AML from MDS in 11, and MDS in 11 (RAEB
in 8, RAEB-t in 1, CMML in 1). Five-year overall survival (OS),
disease-free survival (DFS), and relapse rate (RR) were 79.1%,
76.3%, and 15.2% in AML in remission, and 41.9%, 34.4%, and
46.4% in AML not in remission. These rates were 43.6%, 43.6%,
and 0% in AML from MDS and 71.6%, 72.7%, and 10% in
advanced MDS. For AML in remission, no risk factor affecting OS
and RR was observed, whereas both high-risk karyotype abnormal-
ity and high numbers of blasts in the peripheral blood negatively
affected OS, and these 2 factors and absence of chronic GVHD
signiﬁcantly increased RR in AML not in remission. Conclusions:
These data suggest that TBI and G-CSF combined high-dose
cytarabine is a highly effective regimen for allo-HSCT for AML in
remission, AML evolving from MDS, and advanced MDS with a
notably low incidence of relapse.
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THE USE OF AUTOLOGOUS LMP2-SPECIFIC CYTOTOXIC T LYMPHO-
CYTES FOR THE TREATMENT OF RELAPSED EBV HODGKIN’S DISEASE
AND NON-HODGKIN’S LYMPHOMA
Bollard, C.M.1,3; Straathof, K.C.1; Huls, H.1; Gresik, V.3; Carrum,
G.1,2; Gottschalk, S.1,3; Gee, A.1; Brenner, M.K.1,2,3; Rooney, C.M.1,3;
Heslop, H.E.1,2,3 1. Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX; 2. Methodist Hospital, Houston, TX; 3. Texas
Children’s Hospital, Houston, TX.
EBV-associated Hodgkin’s disease (HD) and some cases of
non-Hodgkins lymphoma (NHL) show type II latency express-
ing the subdominant EBV antigens EBNA1, LMP1, and LMP2,
which may serve as targets for immunotherapy approaches. In
previous studies, we used polyclonal EBV-speciﬁc CTL in pa-
tients with relapsed EBVHD and saw 2 complete and 1 partial
responses in 11 patients. Analyses of EBV-CTL lines showed
that small populations of T cells reactive against the tumor-
associated antigen LMP2 were present in most of the infused
lines, with some expansion in the peripheral blood after infu-
sion. We therefore hypothesized that CTL speciﬁcally targeting
LMP2 might have greater efﬁcacy in these patients. LMP2-
CTLs were generated from 10 patients using dendritic cells and
lymphoblastoid cell lines (LCLs) that had been genetically mod-
iﬁed to overexpress LMP2 by transduction with an
Ad5f35LMP2 vector. Polyclonal LMP2-CTL lines recognized
2–6 (median, 4) LMP2 epitopes, as determined using overlap-
ping LMP2 peptide pools in ELISPOT assays. A mean of 22.8%
(range, 5%-42.1%) of CD8 T cells bound HLA-restricted
LMP2 tetramers, compared with a mean of 0.11% (range,
0.01%-0.24%) of LMP2-tetramer positive CD8 T cells found
in CTLs generated with genetically unmodiﬁed LCLs from the
same patients. So far, 6 patients have been treated with 2 doses
of 2  107 CTL/m2 2 weeks apart. No immediate toxicity was
observed. In patients with identiﬁed LMP2 epitopes, measure-
ment of IFN secretion by CD8 T cells after stimulation with
appropriate LMP2 peptides in ELISPOT assays showed a 4- to
25-fold increase in spot-forming cells after infusions. In con-
trast, frequencies of CMV and superantigen-speciﬁc T cells did
not increase. Four patients without radiologic evidence of dis-
ease who received CTL as adjuvant therapy post-SCT or che-
motherapy remain well up to 12 months post-CTL. Two pa-
tients with measurable disease at the time of CTL infusion had
stable disease 8 weeks post-CTL. They received 2 further doses
of LMP2-CTL. One patient continues with stable disease, and
the other patient had a complete radiologic response. This
patient had a supraclavicular lymph node resection that showed
selective accumulation of LMP2 tetramer-positive cells (0.3%,
compared to 0.01% in the peripheral blood) with few residual
tumor cells. Immunotherapy with autologous LMP2-CTL is
therefore well tolerated in patients with relapsed EBV HD/
NHL, and infused LMP2-CTL cells can localize to the tumor
and induce a clinical response.
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REPAIR OF CROHN’S DISEASE WITH EMBRYONIC STEM CELLS
Feng, Z.; Arrunategui-Correa, V.; Kim, H.S.; Carrier, E. University of
California, San Diego, La Jolla, CA.
The primary objective of this work is to determine differentiation
and repair potential of murine embryonic stem cells (ES) in murine
Crohn’s disease (CD) model. Methods: Colitis was induced in
IL10/ knock-out mice using piroxicam. The colitis in this
model is patchy and progressive and leads to death unless rescue
therapy is provided. Enhanced yellow ﬂuorescent protein (EYFP)
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